Gilead Switch Study (QUAD)

Phase 3b Open-Label Study which will Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI/r) plus FTC/TDF to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen in Virologically-Suppressed, HIV-1 Infected Patients. (Open for enrollment).